Drug intelligence / Profile preview

gemcitabine + paclitaxel + trastuzumab

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A triplet combination chemotherapy regimen consisting of gemcitabine, paclitaxel, and trastuzumab. This regimen is primarily used for treating HER2-overexpressing metastatic breast cancer. Each component has a distinct mechanism of action: gemcitabine is a deoxycytidine analog antimetabolite that damages cancer cells during DNA synthesis; paclitaxel is a taxane that damages the structure supporting cancer cells; and trastuzumab is a monoclonal antibody that selectively binds to HER2 proteins, blocking signals that cause cancer cell multiplication.

Brand names: TaxolGemzarHerceptin
Other names: paclitaxel/gemcitabine/trastuzumabTaxol/Gemzar/HerceptinPTG

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNARNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on gemcitabine + paclitaxel + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + paclitaxel + trastuzumab.

Explore the full profile